Virpax Pharmaceuticals, Inc. (VRPX)

NASDAQ: VRPX · Real-Time Price · USD
0.310
-0.016 (-5.00%)
At close: Feb 18, 2025, 4:00 PM
0.285
-0.025 (-8.00%)
After-hours: Feb 18, 2025, 7:59 PM EST
-5.00%
Market Cap 1.52M
Revenue (ttm) n/a
Net Income (ttm) -13.24M
Shares Out 4.89M
EPS (ttm) -5.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,149,763
Open 0.300
Previous Close 0.326
Day's Range 0.280 - 0.333
52-Week Range 0.230 - 5.480
Beta 0.92
Analysts Hold
Price Target n/a
Earnings Date Mar 25, 2025

About VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal s... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 17, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol VRPX
Full Company Profile

Financial Performance

Financial Statements

News

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate

On Friday, Virpax Pharmaceuticals, Inc.  VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing C...

4 days ago - Benzinga

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...

5 days ago - Business Wire

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...

18 days ago - Business Wire

Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering

NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement ...

19 days ago - GlobeNewsWire

Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...

19 days ago - Business Wire

Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...

21 days ago - Business Wire

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...

3 months ago - Business Wire

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing pharmaceutical products for pain management, announced that ...

3 months ago - Business Wire

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceutical...

3 months ago - GlobeNewsWire

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...

3 months ago - Business Wire

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...

3 months ago - Business Wire

This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Other symbols: FDSBXDQ
4 months ago - Benzinga

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 Second Quarter Results and Recent Developments.

6 months ago - Business Wire

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at Sidoti Virtual Investor Conference August 14-15.

6 months ago - Business Wire

Virpax Regains Compliance with Nasdaq Minimum Bid Price

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Regains Compliance with Nasdaq Minimum Bid Price.

7 months ago - Business Wire

Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.

7 months ago - Benzinga

Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?

Wednesday, Virpax Pharmaceuticals Inc VRPX released results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide immed...

7 months ago - Benzinga

What's Going With Penny Stock Virpax Pharmaceuticals On Monday?

Shares of Virpax Pharmaceuticals Inc  VRPX are trading higher on Monday on a strong session volume of 22.8 million, as per data from Benzinga Pro.

8 months ago - Benzinga

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding.

8 months ago - Business Wire

Virpax® Pharmaceuticals to Present at 2024 BIO International Convention

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.

9 months ago - Business Wire

Virpax Announces Pricing of $2.25 Million Public Offering

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Pricing of $2.25M Public Offering.

9 months ago - Business Wire

Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 First Quarter Results and Recent Developments.

10 months ago - Business Wire

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Results of MTD Study for Probudur. Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief.

10 months ago - Business Wire

Virpax Pharmaceuticals Reports 2023 Year-End Results

BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2023 Year-End Results.

11 months ago - Business Wire

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price.

1 year ago - Business Wire